BioScience Research Centre, GVP College of Engineering Campus and Department of Medicine, Gayatri Vidya Parishad Hospital, Visakhapatnam, India.
BioScience Research Centre, GVP College of Engineering Campus and Department of Medicine, Gayatri Vidya Parishad Hospital, Visakhapatnam, India; UND Life Sciences, Battle Ground, Washington, USA.
Nutrition. 2019 Oct;66:203-218. doi: 10.1016/j.nut.2019.05.007. Epub 2019 Jun 5.
The aim of this study was to investigate the effects of arachidonic acid (AA)-rich ARASCO oil on high-fat diet (HFD) + streptozotocin (STZ)-induced diabetes mellitus in male Wistar rats and its possible mechanisms of action.
Male Wistar rats with HFD + STZ-induced diabetes were employed in the present study. ARASCO oil was administered orally for the first 7 d consecutively, followed by once weekly throughout the study (14 wk). At various time points, blood glucose and body weight and oral glucose tolerance tests were measured. At the end of the study, animals were sacrificed to collect plasma and various organs and stored at -80°C. Plasma insulin, tumor necrosis factor-α, interleukin-6, and lipoxin A4 were measured. Expression of the following genes was determined: nuclear factor-κΒ (NF-κB), cyclooxygenase-2 (COX-2), 12-lipoxygenase (12-LOX) in pancreas and lipocalin 2 (LPCLN2) in adipose tissue. Various antioxidants were measured in the plasma and other tissues. Area under the curve and insulin sensitivity index were assessed by computing homeostatic model of assessment for insulin resistance, quantitative insulin check index, Matsuda, and Belfiore indices.
ARASCO oil treatment decreased hyperglycemia, restored insulin sensitivity, suppressed inflammation, enhanced plasma lipoxin A4 levels, and reversed altered antioxidant status to near normal in animals with HFD + STZ-induced diabetes.
These results suggest that ARASCO, a rich source of AA, can prevent HFD + STZ-induced diabetes in Wistar rats owing to its anti-inflammatory action. It remains to be seen whether ARASCO oil is useful in preventing or postponing the development of type 2 diabetes mellitus in humans.
本研究旨在探讨富含花生四烯酸(AA)的 ARASCO 油对高脂肪饮食(HFD)+链脲佐菌素(STZ)诱导的雄性 Wistar 大鼠糖尿病的影响及其可能的作用机制。
本研究采用 HFD+STZ 诱导糖尿病的雄性 Wistar 大鼠。ARASCO 油连续口服给药 7 天,随后每周一次给药,持续整个研究(14 周)。在不同时间点测量血糖和体重以及口服葡萄糖耐量试验。研究结束时,处死动物收集血浆和各种器官并储存在-80°C。测量血浆胰岛素、肿瘤坏死因子-α、白细胞介素-6 和脂氧素 A4。测定以下基因的表达:核因子-κB(NF-κB)、环氧化酶-2(COX-2)、12-脂氧合酶(12-LOX)在胰腺和脂肪组织中的脂钙蛋白 2(LPCLN2)。测定血浆和其他组织中的各种抗氧化剂。通过计算胰岛素抵抗的稳态模型评估、定量胰岛素检查指数、Matsuda 和 Belfiore 指数评估曲线下面积和胰岛素敏感性指数。
ARASCO 油治疗可降低高血糖,恢复胰岛素敏感性,抑制炎症,增加血浆脂氧素 A4 水平,并使 HFD+STZ 诱导糖尿病动物的抗氧化状态恢复正常。
这些结果表明,富含 AA 的 ARASCO 可通过抗炎作用预防 Wistar 大鼠的 HFD+STZ 诱导糖尿病。ARASCO 油是否可用于预防或延缓人类 2 型糖尿病的发生仍有待观察。